Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

731 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita.
Zillikens H, Kasprick A, Osterloh C, Gross N, Radziewitz M, Hass C, Hartmann V, Behnen-Härer M, Ernst N, Boch K, Vidarsson G, Visser R, Laskay T, Yu X, Petersen F, Ludwig RJ, Bieber K. Zillikens H, et al. Among authors: gross n. Front Med (Lausanne). 2021 Sep 7;8:713312. doi: 10.3389/fmed.2021.713312. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34557502 Free PMC article.
Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.
Ghorbanalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil'chenko S, Kasprick A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E, Ludwig RJ. Ghorbanalipoor S, et al. Among authors: gross n. Front Immunol. 2022 Sep 28;13:865241. doi: 10.3389/fimmu.2022.865241. eCollection 2022. Front Immunol. 2022. PMID: 36248903 Free PMC article.
Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.
Ghorbanalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil'chenko S, Kasprick A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E, Ludwig RJ. Ghorbanalipoor S, et al. Among authors: gross n. Front Immunol. 2022 Nov 30;13:1099535. doi: 10.3389/fimmu.2022.1099535. eCollection 2022. Front Immunol. 2022. PMID: 36532003 Free PMC article.
High throughput screening identifies repurposable drugs for modulation of innate and acquired immune responses.
Ghorbanalipoor S, Matsumoto K, Gross N, Heimberg L, Krause M, Veldkamp W, Magens M, Zanken J, Neuschutz KJ, De Luca DA, Kridin K, Vidarsson G, Chakievska L, Visser R, Kunzel S, Recke A, Gupta Y, Boch K, Vorobyev A, Kalies K, Manz RA, Bieber K, Ludwig RJ. Ghorbanalipoor S, et al. Among authors: gross n. J Autoimmun. 2024 Sep;148:103302. doi: 10.1016/j.jaut.2024.103302. Epub 2024 Aug 19. J Autoimmun. 2024. PMID: 39163739 Free article.
Annexin V expression on CD4+ T cells with regulatory function.
Bollinger AL, Bollinger T, Rupp J, Shima K, Gross N, Padayachy L, Chicheportiche R, Puga Yung GL, Seebach JD. Bollinger AL, et al. Among authors: gross n. Immunology. 2020 Feb;159(2):205-220. doi: 10.1111/imm.13140. Epub 2019 Nov 20. Immunology. 2020. PMID: 31642515 Free PMC article.
731 results